share_log

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

SEC announcement ·  May 8 20:58
Summary by Futu AI
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced a tender offer to acquire all issued and outstanding shares of Alpine Immune Sciences, Inc. at a price of $65.00 per share in cash. The offer, detailed in an amendment to the Schedule TO filed with the SEC on April 22, 2024, is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. The amendment supplements previous disclosures, including the expected filing of Premerger Notification and Report Forms under the HSR Act by April 24, 2024, and provides additional information on the background of the offer and regulatory approvals. The offer's terms and conditions, including the potential extension of the expiration time, are outlined in the Offer to Purchase. Vertex has also filed related materials with the SEC, including a press release and excerpts from their Q1 earnings call on May 6, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.